A guide to immunotherapy for COVID-19

Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in cli...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature medicine Jg. 28; H. 1; S. 39 - 50
Hauptverfasser: van de Veerdonk, Frank L., Giamarellos-Bourboulis, Evangelos, Pickkers, Peter, Derde, Lennie, Leavis, Helen, van Crevel, Reinout, Engel, Job J., Wiersinga, W. Joost, Vlaar, Alexander P. J., Shankar-Hari, Manu, van der Poll, Tom, Bonten, Marc, Angus, Derek C., van der Meer, Jos W. M., Netea, Mihai G.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: New York Nature Publishing Group US 01.01.2022
Nature Publishing Group
Schlagworte:
ISSN:1078-8956, 1546-170X, 1546-170X
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Immune dysregulation is an important component of the pathophysiology of COVID-19. A large body of literature has reported the effect of immune-based therapies in patients with COVID-19, with some remarkable successes such as the use of steroids or anti-cytokine therapies. However, challenges in clinical decision-making arise from the complexity of the disease phenotypes and patient heterogeneity, as well as the variable quality of evidence from immunotherapy studies. This Review aims to support clinical decision-making by providing an overview of the evidence generated by major clinical trials of host-directed therapy. We discuss patient stratification and propose an algorithm to guide the use of immunotherapy strategies in the clinic. This will not only help guide treatment decisions, but may also help to design future trials that investigate immunotherapy in other severe infections. This Review aims to support clinical decision-making by providing an overview of the evidence for immunotherapy strategies in patients with COVID-19.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1078-8956
1546-170X
1546-170X
DOI:10.1038/s41591-021-01643-9